Annual EBIT
-$18.49 M
-$957.20 K-5.46%
01 December 2023
Summary:
TransCode Therapeutics annual earnings before interest & taxes is currently -$18.49 million, with the most recent change of -$957.20 thousand (-5.46%) on 01 December 2023. During the last 3 years, it has fallen by -$11.74 million (-174.00%). RNAZ annual EBIT is now -4007.11% below its all-time high of -$450.20 thousand, reached on 31 December 2019.RNAZ EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$2.31 M
+$2.88 M+55.45%
01 September 2024
Summary:
TransCode Therapeutics quarterly earnings before interest & taxes is currently -$2.31 million, with the most recent change of +$2.88 million (+55.45%) on 01 September 2024. Over the past year, it has increased by +$1.76 million (+43.23%). RNAZ quarterly EBIT is now -182.14% below its all-time high of $2.81 million, reached on 30 June 2021.RNAZ Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$14.88 M
+$2.97 M+16.64%
01 September 2024
Summary:
TransCode Therapeutics TTM earnings before interest & taxes is currently -$14.88 million, with the most recent change of +$2.97 million (+16.64%) on 01 September 2024. Over the past year, it has increased by +$3.61 million (+19.50%). RNAZ TTM EBIT is now -90107.27% below its all-time high of -$16.50 thousand, reached on 01 March 2020.RNAZ TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RNAZ EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +43.2% | +19.5% |
| 3 y3 years | -174.0% | +17.5% | -120.6% |
| 5 y5 years | -4007.1% | - | - |
RNAZ EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -174.0% | at low | at high | +56.3% | -157.2% | +23.7% |
| 5 y | 5 years | -4007.1% | at low | -182.1% | +56.3% | <-9999.0% | +23.7% |
| alltime | all time | -4007.1% | at low | -182.1% | +56.3% | <-9999.0% | +23.7% |
TransCode Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.31 M(-55.4%) | -$14.88 M(-16.6%) |
| June 2024 | - | -$5.19 M(+56.4%) | -$17.86 M(+5.0%) |
| Mar 2024 | - | -$3.32 M(-18.5%) | -$17.00 M(-8.0%) |
| Dec 2023 | -$18.49 M(+5.5%) | -$4.07 M(-23.0%) | -$18.49 M(-5.2%) |
| Sept 2023 | - | -$5.28 M(+21.9%) | -$19.51 M(+5.3%) |
| June 2023 | - | -$4.33 M(-9.8%) | -$18.53 M(-1.8%) |
| Mar 2023 | - | -$4.80 M(-5.7%) | -$18.87 M(+7.6%) |
| Dec 2022 | -$17.53 M | -$5.09 M(+18.4%) | -$17.53 M(+15.0%) |
| Sept 2022 | - | -$4.30 M(-8.0%) | -$15.24 M(+14.8%) |
| June 2022 | - | -$4.67 M(+34.6%) | -$13.27 M(+129.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$3.47 M(+24.0%) | -$5.79 M(-14.3%) |
| Dec 2021 | -$6.75 M(+246.2%) | -$2.80 M(+20.2%) | -$6.75 M(+43.7%) |
| Sept 2021 | - | -$2.33 M(-182.8%) | -$4.70 M(+35.7%) |
| June 2021 | - | $2.81 M(-163.5%) | -$3.46 M(-45.6%) |
| Mar 2021 | - | -$4.43 M(+492.8%) | -$6.37 M(+226.5%) |
| Dec 2020 | -$1.95 M(+333.0%) | - | - |
| Dec 2020 | - | -$747.70 K(-31.6%) | -$1.95 M(+62.2%) |
| Sept 2020 | - | -$1.09 M(+1095.2%) | -$1.20 M(+1012.6%) |
| June 2020 | - | -$91.50 K(+454.5%) | -$108.00 K(+554.5%) |
| Mar 2020 | - | -$16.50 K | -$16.50 K |
| Dec 2019 | -$450.20 K | - | - |
FAQ
- What is TransCode Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly EBIT year-on-year change?
- What is TransCode Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for TransCode Therapeutics?
- What is TransCode Therapeutics TTM EBIT year-on-year change?
What is TransCode Therapeutics annual earnings before interest & taxes?
The current annual EBIT of RNAZ is -$18.49 M
What is the all time high annual EBIT for TransCode Therapeutics?
TransCode Therapeutics all-time high annual earnings before interest & taxes is -$450.20 K
What is TransCode Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of RNAZ is -$2.31 M
What is the all time high quarterly EBIT for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly earnings before interest & taxes is $2.81 M
What is TransCode Therapeutics quarterly EBIT year-on-year change?
Over the past year, RNAZ quarterly earnings before interest & taxes has changed by +$1.76 M (+43.23%)
What is TransCode Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of RNAZ is -$14.88 M
What is the all time high TTM EBIT for TransCode Therapeutics?
TransCode Therapeutics all-time high TTM earnings before interest & taxes is -$16.50 K
What is TransCode Therapeutics TTM EBIT year-on-year change?
Over the past year, RNAZ TTM earnings before interest & taxes has changed by +$3.61 M (+19.50%)